Parkinson's disease

FDA Issues Statement Addressing Safety Concerns Associated With Nuplazid

By September 21, 2018

Based on the data, the FDA has concluded that the drug's benefit continues to outweigh its risks for patients with hallucinations and delusions associated with Parkinson's disease psychosis.

FDA Approves New Nuplazid Formulation, Dosage Strength

By June 29, 2018

Nuplazid, a non-dopaminergic, selective serotonin inverse agonist, targets 5-HT2A receptors that are thought to be involved in Parkinson's disease psychosis.

FDA to Review Sublingual Tx for Motor Fluctuations in Parkinson's Disease

By June 13, 2018

The film is a new formulation of the dopamine agonist apomorphine, intended for rapid conversion from the OFF to the ON state; it has been studied to treat motor OFF episodes up to 5 times a day.

Exposure to Anti-TNF Therapy Linked to Reduced Parkinson's Disease Risk

By April 24, 2018

Previous research has suggested a genetic and functional link between IBD and PD, however evidence regarding this association has been limited.

Long-Term Benefits of Gocovri Observed in PD Patients With Dyskinesia

By April 19, 2018

By 2 years, 30% of patients had increased their levodopa dose by ~300mg, indicating that treatment with Gocovri may allow for further levodopa optimization despite the occurrence of dyskinesia.

NDA Submitted for Sublingual Film to Treat OFF Episodes in Parkinson's Disease

By March 30, 2018

The NDA submission included data from Phase 3, 12-week, randomized, double-blind, placebo-controlled, parallel-group study (CTH-300) that enrolled patients with levodopa-responsive Parkinson's disease complicated by OFF episodes.

FDA to Review Xeomin for the Management of Excessive Drooling

By March 14, 2018

The sBLA is based on a Phase 3, randomized, double-blind, placebo-controlled, multicenter 184 subject trial.

Osmolex ER OK'd for Parkinson's Disease, Drug-Induced Extrapyramidal Reactions

By February 20, 2018

The approval of Osmolex ER was based on bioavailability studies comparing Osmolex ER to immediate-release amantadine.

Apomorphine Film Effectively Converts OFF to ON State in PD Patients

By January 30, 2018

The difference in score change for movement disorder from baseline to 30 minutes post-dose between the apomorphine and placebo group was 7.6 (P=0.0002).

Gocovri Now Available to Treat Dyskinesia in Parkinson's Disease Patients

By January 09, 2018

Gocovri is indicated for the treatment of dyskinesia in patients with Parkinson's disease receiving levodopa-based therapy, with or without concomitant dopaminergic medications.

Gocovri Approved to Treat Dyskinesia in Patients with Parkinson's Disease

By August 28, 2017

The safety and efficacy of Gocovri was seen in two Phase 3 controlled trials in Parkinson's disease patients with dyskinesia.

Opicapone As Levodopa Adjunct Cuts Motor Fluctuations in PD

December 28, 2016

In Parkinson's disease, 50mg/day opicapone linked to significant reduction in mean daily off-time

FDA Approves First Treatment for Parkinson's Disease Psychosis

By May 02, 2016

It is the first treatment to be approved for this indication.

Some Parkinson's Disease Meds May Up Risk of Compulsive Behaviors

By April 06, 2016

Neurologists have linked medications used for Parkinson's disease with impulse control disorders such as pathological gambling, compulsive buying, hypersexuality, and binge eating in some patients.

FDA Committee Votes in Favor of Nuplazid for Parkinson's Disease Psychosis

By March 30, 2016

Acadia announced that the Food and Drug Administration (FDA) Psychopharmacologic Drugs Advisory Committee (PDAC) voted in favor (12-2) that the benefits of Nuplazid (primavanserin) outweighed the risks for the treatment of psychosis associated with Parkinson's' disease.

Speech for Parkinson's Patients Impacted More by Cognitive vs. Physical Impairment

March 21, 2016

Declines in cognition could have a greater impact on the ability of Parkinson's disease patients to converse than physical impairment, according to research published online in the Journal of Parkinson's Disease.

New Dementia Prediction Algorithm Proves Promising Accuracy

January 25, 2016

Researchers from University College London have developed an algorithm that uses medical data to predict a five-year risk of dementia, according to a report published online January 21 in BMC Medical.

Lower Risk of Falls for Parkinson's Patients With Dementia Rx

January 14, 2016

Rivastigmine shows potential in reducing the risk of falls among patients with Parkinson's disease, according to new research published online January 12 in The Lancet Neurology.

A Compound in Chamomile May Benefit Brain Cells

By December 11, 2015

Apigenin, a flavonoid found in some spices and herbs, may improve neuron formation and strengthen connections between brain cells, researchers from D'Or Institute for Research and Education reported.

Acupuncture Improves Gait Function in Parkinson's Disease

October 30, 2015

Significant improvement in gait speed, step length, floor reaction force, and cadence

Safinamide NDA Resubmitted for Parkinson's Disease

By December 29, 2014

Newron announced the resubmission of its NDA for safinamide to the FDA.